A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB 16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

16861BGB-16673-304-NCT06973187OpenA Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB 16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaBGB-16673-304NCT06973187IndustrialAdultTreatmentIIILymphoid Leukemia; Non-Hodgkin LymphomaDunleavy, KieronGeorgetown University Medical Center : Ayodeji Olukoya; Lombardi Comprehensive Cancer Center : Ayodeji OlukoyaLeukemia; LymphomaOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16185Ayodeji OlukoyaAyodeji Olukoyaaoo42@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>